Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Carcinoma, Renal Cell 3Recurrence 1Prostatic Hyperplasia 1Ovarian Neoplasms 1Mesothelioma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

polyphenon E 1mirabegron 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1TroVax 1Radiotherapy 1Needles 1Electroacupuncture 1Doxazosin 1Docetaxel 1Celecoxib 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Hyperplasia × TroVax × Clear all
NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡